PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

5-ASA Delivers Deep Objective Remission, But Urgency Persists in UC

5-aminosalicylic acidmesalamineulcerative colitisinflammatory bowel diseasecross-sectional studytreat-to-targetdeep remissionbowel urgencyreal-world evidence Gastroenterology / Hepatology

Background Information

5-ASA shows strong remission rates but struggles with deep remission in UC.

This study evaluates the real-world effectiveness of 5-aminosalicylic acid (5-ASA) in achieving clinical goals in patients with ulcerative colitis (UC). High rates of biological (78%), endoscopic (87%), and histological (80%) remission were observed, but deep remission was only 24% due to persistent urgency. The results confirm 5-ASA's relevance in mild-to-moderate UC and emphasize the need to manage residual symptoms despite mucosal healing. 5-ASA effectively induces remission but residual symptoms remain a challenge.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Reenaers C, Lambrecht G, Pouillon L, Baert F, Cremer A, Colard A, Claessens C, Billiet T, Geldof J, De Zutter A, Rahier JF, Somers M, Reynders D, Vansteenkiste L, Arijs I, Louis E, Belgian IBD Research and Development Group (BIRD), Verstockt B

Citation: Reenaers C, Lambrecht G, Pouillon L, et al. Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group. Journal of Crohn's & colitis. 2026;20(8). doi:10.1093/ecco-jcc/jjag100

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.